Eric Monflier

Prof. Dr. Eric Monflier

Univ. Artois
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2006 in Chemical Reviews
Verified
Journal Article
Closed access
FHFrédéric Hapiot
Frédéric Hapiot
STSebastien Tilloy
Sebastien Tilloy
EMEric Monflier
Eric Monflier

1 September 2017 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MMMhamad Aly Moussawi
Mhamad Aly Moussawi
NLNathalie Leclerc-Laronze
Nathalie Leclerc-Laronze
SFSébastien Floquet
Sébastien Floquet
Pavel A. AbramovPavel A. Abramov
Pavel A. Abramov
MSMaxim N. Sokolov
Maxim N. Sokolov
ECEmmanuel Cadot
Emmanuel Cadot

20 December 2016 in Molecules
Verified
Journal Article
Open access
PDF file
CCCaroline Coisne
Caroline Coisne
STSebastien Tilloy
Sebastien Tilloy
EMEric Monflier
Eric Monflier
DWDaniel Wils
Daniel Wils
LTLaurence Tilloy-Fenart
Laurence Tilloy-Fenart
FGFabien Gosselet
Fabien Gosselet
Cardiovascular diseases, like atherosclerosis, and neurodegenerative diseases affecting the central nervous system (CNS) are closely linked to alterations of cholesterol metabolism. Therefore, innovative pharmacological approaches aiming at counteracting cholesterol imbalance display promising therapeutic potential. However, these approaches need to take into account the existence of biological barriers such as intestinal and blood-brain barriers which participate in the organ homeostasis and are major defense systems against xenobiotics. Interest in cyclodextrins (CDs) as medicinal agents has increased continuously based on their ability to actively extract lipids from cell membranes and to provide suitable carrier system for drug delivery. Many novel CD derivatives are constantly generated with the objective to improve CD bioavailability, biocompatibility and therapeutic outcomes. Newly designed drug formulation complexes incorporating CDs as drug carriers have demonstrated better efficiency in treating cardiovascular and neurodegenerative diseases. CD-based therapies as cholesterol-sequestrating agent have recently demonstrated promising advances with KLEPTOSE® CRYSMEB in atherosclerosis as well as with the 2-hydroxypropyl-β-cyclodextrin (HPβCD) in clinical trials for Niemann-Pick type C disease. Based on this success, many investigations evaluating the therapeutical beneficial of CDs in Alzheimer’s, Parkinson’s and Huntington’s diseases are currently on-going.

6 January 2012 in Environmental Chemistry Letters
Verified
Journal Article
Closed access
PDF file
DLDavid LANDY
David LANDY
IMIsabelle Mallard
Isabelle Mallard
APAnne Ponchel
Anne Ponchel
EMEric Monflier
Eric Monflier
SFSophie Fourmentin
Sophie Fourmentin

5 October 2017 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MMMhamad Aly Moussawi
Mhamad Aly Moussawi
MHMohamed Haouas
Mohamed Haouas
SFSebastien Floquet
Sebastien Floquet
WSWilliam E. Shepard
William E. Shepard
Pavel A. AbramovPavel A. Abramov
Pavel A. Abramov
ECEmmanuel Cadot
Emmanuel Cadot

4 April 2014 in Catalysis Science & Technology
Verified
Journal Article
Closed access
PDF file
FHFrédéric Hapiot
Frédéric Hapiot
HBHervé Bricout
Hervé Bricout
SMStephane MENUEL
Stephane MENUEL
STSebastien Tilloy
Sebastien Tilloy
EMEric Monflier
Eric Monflier
During the past twenty years, cyclodextrins (CDs) have proven to be very effective in aqueous biphasic catalysis. They could act as molecular receptors for numerous organic substrates and favour their conversion at the aqueous/organic interface. Recently, new applications have been found for CDs in aqueous catalysis. CDs can now be defined as polyfunctional entities between the substrate-containing phase and the catalyst-containing phase. In this paper, we highlight the latest breakthroughs in the use of CDs in catalysis through several examples from the literature.